Pulmonary artery denervation for treatment of a patient with pulmonary hypertension secondary to left heart disease

Pulmonary Circulation

Volumn 6, Issue 2, 2016, Pages 240-243

  Zhang, Hang ^a   Zhang, Juan ^a   Xie, Du Jiang ^a   Jiang, Xiaoming ^a   Zhang, Feng Fu ^a   Chen, Shao Liang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Heart failure; Pulmonary artery denervation; Pulmonary hypertension

Indexed keywords

EID: 84977479042     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/685550     Document Type: Article

References (13)

1. Ghio S. Pulmonary hypertension in advanced heart failure. Herz 2005; 30: 311-317.
2. Vachiéry JL, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 2013; 62(25 suppl.): D100-D108.
3. Guazzi M, Vitelli A, Labate V, Arena R. Treatment for pulmonary hypertension of left heart disease. Curr Treat Options Cardiovasc 2012; 14: 319-327.
4. Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T, Stone GW, et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol 2013; 62: 1092-1100.
5. Guazzi M. Pulmonary hypertension in heart failure preserved ejection fraction prevalence, pathophysiology, and clinical perspectives. Circ Heart Fail 2014; 7: 367-377.
6. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2015; 46: 903-975.
7. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134: 44-54.
8. Haddad F, Kudelko K, Mercier O, Vrtovec B, Zamanian RT, de Jesus Perez V. Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies. Prog Cardiovasc Dis 2011; 54: 154-167.
9. Wu X, Yang T, Zhou Q, Li S, Huang L. Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. Eur J Heart Fail 2014; 16: 444-453.
10. Juratsch CE, Jengo JA, Castagna J, Laks MM. Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature. Chest 1980; 77(4): 525-530.
11. Chen SL, Zhang YJ, Zhou L, Xie DJ, Zhang FF, Jia HB, Wong SS, Kwan TW. Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo. EuroIntervention 2013; 9: 269-276.
12. Rothman AM, Arnold ND, Chang W, Watson O, Swift AJ, Condliffe R, Elliot CA, et al. Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension. Circ Cardiovasc Interv 2015; 8: e002569.
13. Chen SL, Zhang H, Xie DJ, Zhang J, Zhou L, Rothman AM, Stone GW. Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study. Circ Cardiovasc Interv 2015; 8: e002837.